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Introduction
 In the mid 1800’s cells were discovered to be the building blocks 
of life. It was then later discovered that in addition to this simple role, 
some cells were found to have the ability to self-renew and proliferate. 
We now refer to these cells more commonly as stem cells, this term 
being coined for use in the scientific world by histologist Alexander 
Maksimov in 1908 [1]. 
As research in this field of stem cells progressed Ramon y Cajal, 
known to many as the father of Neuroscience, made a profound 
statement affirming: ‘In adult centres the nerve paths are something 
fixed, ended, immutable. Everything may die, nothing may be 
regenerated’. However, since this statement there is much evidence that 
has proved it to be inaccurate, as in fact encouraged by Cajal himself: ‘It 
is for the science of the future to change, if possible, this harsh decree’.
Altman and Das carried one of the earliest studies In 1965 that 
disproved Cajal’s statement, but unfortunately was not given much 
attention, In this study rats were injected with thymidine- H3 resulting 
in a great number of the granule cells of the dentate gyrus being labeled. 
As the rat aged from the time the injection was given, the number of 
labeled granule cells was found to decrease. On further analysis it was 
found that the cells, which were undifferentiated and in close proximity 
to the granular layer of the dentate gyrus displayed a fast rise in number 
which was then followed by a decline. This decline in undifferentiated 
cells was found to occur simultaneously to the increase in differentiated 
cells. From the study they concluded that undifferentiated cells 
postnatal move towards the hippocampus from the forebrain ventricles, 
where they go on to differentiate [2]. This study was one of the earliest 
experiments showing evidence for the occurrence of neurogenesis.
A more recent case showing evidence of neurogenesis was in a 
patient who was minimally conscious for 19 years. Overtime he showed 
improvements in his speech and language. Through the use of PET 
and MRI scans central nervous system (CNS) remodeling and axonal 
growth could be seen [3]. As time progressed more evidence was shown 
that stem cells do exist and could be obtained from a variety of sources.
The next obstacle to overcome was to create pluripotent stem cell 
lines. This was achieved in 1998 when the first embryonic stem cell 
line was developed from cells isolated from the inner cell mass of early 
embryos. These cells were described to manifest elevated levels of 
telomerase activity, have regular karyotypes, and express cell surface 
markers that are characteristics of early primate embryonic stem 
cells (ESCs) but no other early cell lineages. These cells underwent 
undifferentiated cell proliferation for approximately 4 to 5 months and 
were still able to mature into trophoblasts and derivatives of endoderm, 
mesoderm and ectoderm [4]. 
During that same year research was undertaken involving 
primordial germ cells extracted from mesenteries and gonadal ridges. 
These primordial germ cells were cultured and found to grow into large 
multicellular colonies that resembled pluripotent stem cells known 
as embryonic stem and embryonic germ cells. They were found to 
have the characteristics pluripotent stem cells should have, closely 
resembling embryonic germ cells: throughout culture they remained 
alkaline phosphate positive and they were positive for 5 immunological 
markers that characterize embryonic stem and embryonic germ cells. 
Furthermore they were found to have normal karyotypes and be stable, 
in addition to revealing a wide variety of different cell types, inclusive 
of the three embryonic germ layers [5]. These two early experiments 
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showed great hope for future research into stem cell differentiation and 
cell proliferation. 
The interest in stem cells has continued to grow. One of the main 
reasons for this is the great potential they have to contribute to the 
progress of Medicine. For example, they have so far shown potential 
in the involvement of bone marrow transplants in immunodeficient 
diseases. In 1963 the presence of self-renewing cells were found within 
the bone marrow of mice. Normal mouse blood-forming tissues were 
found to contain a class of cell which, when placed into heavily irradiated 
mice were able to proliferate and become macroscopic colonies in the 
spleen [6]. 5 years following this marked one of the first successful 
bone marrow transplants where a 5-month-old male suffering from 
sex-linked lymphopenic immunological deficiency was treated with 
immunologically competent cells obtained from peripheral blood buffy 
coat and bone marrow of a sibling donor. The result of this was a return 
of cellular and humoral immunity in the 5-month-old patient [7]. 
In addition to bone marrow transplants, stem cells have also shown 
great potential for organ transplantations. Transplantation medicine 
was pioneered when the first electrophysiological experiments were 
able to develop cardiomyocytes from ESCs [8]. 
Another field where stem cells are showing great advancements is in 
the treatment of neurodegenerative disorders, which are characteristic 
of loss of neurons and glia. Amongst all the organs, the CNS shows the 
most difficulty in regeneration [9]. Despite this, there is now promising 
research that indicates it is possible to regenerate the cells of the CNS 
using stem cells. New migrating stem cells have been found within 
the brains of rodent models with induced injury. Furthermore, cells 
derived from the bone marrow have been found to have the ability 
to develop into cells with neuronal and vascular phenotype to help in 
repair of brain injury. Neural stem cells (NSCs) have also been found to 
be of clinical importance because they can migrate and hone towards 
distant areas. They are able to differentiation into neurons and glia and 
in addition to this they are able to rescue injured and dysfunctional 
endogenous neurons, serving as chaperones [10]. Therefore, it can be 
seen that stem cells from a number of sources are now showing great 
potential in the treatment of neurodegenerative diseases.
Stem Cells
As a multicellular organism develops, the cells undergo a sequence 
of programmed events that result in them becoming differentiated, 
forming organs and tissues that make up an adult individual. The 
majority of cells go through this process. However there are a number 
of cells that do not take place in this developmental process but rather 
become reserved precursor cells. These precursor cells can be separated 
into two main categories: lineage-committed progenitor cells and 
lineage uncommitted pluripotent stem cells. 
There is often ambiguity of what exactly defines a stem cell. A 
minimalist definition describes stem cells as cells that have the ability 
to self-renew and have the ability to produce differentiated progeny in 
order to help maintain and repair the tissues and organs throughout an 
individual’s life, a term known as pluripotency [11]. 
Self-renewal involves division of the cell through the process 
of mitosis and maintenance of its pluripotent property. Self-
renewal is of two types: asymmetrical and symmetrical. The ESCs 
divide to form two cells of equal identity whilst adult stem cells 
(ASCs) divide forming a stem cell and a progenitor cell [12]. 
Stem cells having the property of pluripotency mean they have the 
ability to differentiate into derivatives of ectoderm, mesoderm and 
endoderm, totalling to a number of 200 different kinds of cells [12]. 
In addition to these two main properties stem cells are also able 
to: differentiate, renew them, migrate and distribute within the CNS 
once implanted, proliferate, be obtained from the patients, be easily 
manipulated using viral and non-viral gene transfer methods and 
integrate into the cell structure of the brain showing potential of 
regulated release of substances [13]. 
These properties of stem cells are very attractive when it comes to 
finding a treatment for neurodegenerative diseases: those characteristic 
of loss of neurons and glia. If we can find a way to renew and differentiate 
cells those lost neurons and glia then we would be well on the way to 
finding a cure. There are three main sources of where stem cells can be 
obtained: embryonic, adult and umbilical stem cells. 
Embryonic Stem Cells (ESCs)
ESCs are obtained from the inner cell mass of the blastocyst and 
‘embryonic germ cells have been obtained from post-implantational 
embryos’ [13]. ESCs are uncommitted cells and the progenitors of the 
three embryonic germ cell layers: endoderm, ectoderm, and mesoderm. 
Therefore they are able to give rise to all the germ line and somatic cells 
of developed organisms [14]. 
One of the main limitations of the use of ESCs is in the moral and 
ethical complications surrounding their origin [15]. Furthermore, it 
has been found that human ESCs give rise to teratomas meaning that 
they are limited in their use for therapeutic treatment [12].
Fetal stem cells also have ethical issues surrounding them but 
less so ESCs. They are obtained from fetal blood and bone marrow in 
addition to liver and kidney tissue. Within the fetal blood are a large 
supply of haematopoietic stem cells (HSCs) and mesenchymal stem 
cells (MSCs) [16]. 
Adult Stem Cells (ASCs)
ASCs have been found to be present within many of the tissues and 
organs within the human body. Compared to ESCs, ASCs are more 
limited in renewal and differentiation. Their renewal and differentiation 
is usually found to be limited to the cells of the tissue in which they are 
found. When they are able to generate cells from a different tissue to 
their origin, it is referred to as transdifferentiation [12]. For example, 
HSCs have been found to travel to the brain and differentiate into 
neuron-like cells [17]. 
Neural stem cells (NSCs): Present within the adult brain are NSCs, 
which are able to generate neurons and non-neuronal cells (astrocytes 
and oligodendrocytes). This process is known as neurogenesis. 
NSC’s can be found in the subcortical white matter, hippocampus 
and sub ventricular zone. The subventricular zone is home to the 
biggest stem cell niche. NSCs present here are found to differentiate 
into astrocytes. NSC’s found in the hippocampus differentiate into 
neuroblasts which go on to give rise to granule cells [12]. 
NSC’s derived from non-hippocampal regions were expanded 
in culture using different types of growth factors such as fibroblast 
growth factors and epidermal growth factors. They were in fact found 
to be highly expandable, being maintained for 60 population doublings 
with low occurrence of senescence and no reported immortalising 
mutations. The amount of cells produced was found to be enough for 4 
× 107 brains. When transferred into rodent brains they took on glial and 
neuronal phenotypes [10]. 
Bone marrow derived stem cells: Multipotent stem cells  are 
advantageous over NSCs because they can avoid the risk of having 
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to access  the brain in order to be obtained. Examples of multipotent 
stem cells are the mesenchymal stem cells (MSCs). They are obtained 
from the bone marrow and arise from mesoderm making them easily 
accessible [18]. MSCs have the ability to differentiate into cartilage, fat, 
bone and cells supporting the formation of fibrous connective tissue 
and blood [19,20]. They have also been found to be able to differentiate 
into hepatocytes, cardiac and skeletal muscles well as glial and neurons. 
Another advantage of multipotent stem cells is they are immunologically 
inactive. Furthermore, due to autologous transplantation the ethical 
issues associated with fetal and embryonic stem cells are avoided [18]. 
Within the bone marrow of adults one can find HSCs, which are able to 
form all the type of blood cells in the body [19,20].
Induced pluripotent stem cells: Induced pluripotent stem cells 
(IPSCs) are a recent discovery and are obtained from adult cells. On 
introduction of four genes, adult cells gained the ability to differentiate 
into any other cell type. IPSCs are very promising for the treatment of 
neurodegenerative disease as they have the ability to replace those cells 
lost and destroyed during the progression of disease. They have been 
likened to ESCs. However, the advantage that they hold over ESCs is 
they avoid the ethical issues surrounding how ESCs are obtained [21]. 
Umbilical Stem Cells
When newborns are delivered it was always common practice to 
remove the umbilical cord, but since the umbilical cord was found to be 
a source of HSCs this is now no longer always the case. 
Collecting umbilical stem cells involves collecting blood from the 
umbilical cord. The stem cells in the blood are then concentrated and 
preserved in liquid nitrogen at freezing temperatures. This method of 
preservation enables the cells to be stored for years until needed. The 
advantage of this is there is no time lost on finding donors. The number 
of patients treated using stored umbilical stem cells reaches 3000 
and spans around 45 different illnesses. There is hope for the use of 
umbilical stem cells in treating many other pathologies including repair 
of neurons [22]. The downside of umbilical stem cells is their limited 
availability [23]. 
Neurodegenerative Diseases
The CNS is made up neurons and glial cells; which protect 
the neurons by surrounding them. An example of a glial cell is the 
oligodendrocyte whose main function is to increase the time of which 
neuronal signals are sent over extensive distances. Conditions in which 
these nerve cells are lost are referred to as neurodegenerative disorders. 
Much research is going into looking at how these lost nerve cells can be 
replaced. Neural stem cells hold much promise for this [24]. 
NSCs have the ability to generate neurons and glia but this only 
occurs at a few sites within the brain. Therefore much research is being 
undertaken to find methods and techniques in which stem cells grown 
in culture can be implanted into patients brain where they are able 
to differentiate into neurons and glia or finding ways where already 
differentiated neural and glia cells can be implanted [24]. 
We will now look at four main types of neurodegenerative diseases: 
Parkinson’s disease, Huntington’s disease, Multiple sclerosis and 
Alzheimer's disease, and see in turn what are their pathogenesis and 
symptoms, current treatments and the current evidence for the use of 
stem cells as treatment for these neurodegenerative disorders. 
Parkinson’s Disease
Parkinson's disease (PD) affects 1% of the population by the time 
they reach the age of 60 and therefore is found to be the most common 
neurodegenerative movement disorder [25]. It affects mainly motor 
functions where patients present mainly with tremor, rigidity and 
cognitive impairment. It is a slowly progressing disease, first affecting 
the different sides of the body in turn [26]. 
In this disease, at the cellular level, patients show loss of dopamine 
neurons present in the substantia nigra pars compact a within the 
midbrain. There can be observed accumulation of aggregates called Lewy 
bodies, which cause destruction of neurons [9,27]. This disturbance can 
cause changes to the pattern of firing neurons, for example an increase 
of: firing, bursting, synchrony and a leaning towards loss of specificity in 
the receptive fields. This change in the pattern of firing neurons is then 
conveyed to the thalamus, cortex and brainstem and therefore thought 
to disturb the way in which the motor system works, thus leadings to 
the symptoms associated with PD: tremor, rigidity, akinesia [28]. 
However, the conventional idea that degeneration starts in the 
substantia nigra is now being questioned. There is evidence showing 
that there is a spread of alpha synuclein, which starts in the brainstem. 
From here this then goes to the substantia nigra and involves more of 
the cortical areas, thus reflecting the clinical progression of PD. One 
of the first signs of the disease is not one linked to the motor system 
but rather sleep disturbances, autonomic abnormalities and loss of 
sense of smell. It is when it involves the substantia nigra you get typical 
rigidity and bradykinesia. At the end stage is when dementia and high 
cognitive dementia sets in. This again can be associated with the spread 
of aggregation inside the brain, which goes on to affect other areas 
responsible for memory and cognition [25,29]. 
Current treatment
One would think that PD would be an easy disorder to treat, as it is 
loss of just one type of cell population: dopaminergic neurons. However, 
the research has shown that is proving to be much more difficult.
At the moment there is no definitive treatment for PD but rather 
management of symptoms mainly through the use of drugs and surgery. 
As patients suffering from PD suffer from low levels of dopamine 
they are given a precursor of dopamine: L-dihydroxyphenyl alanine 
(L-DOPA). A precursor is given, as dopamine is not able to pass across 
the blood brain barrier. Instead L-DOPA is taken up by the substantia 
nigra and metabolized to dopamine.
Another treatment used for patients suffering from PD is deep 
brain stimulation. It has been found that stimulation of the ventral 
intermediate nucleus of the thalamus can greatly alleviate the symptom 
of tremor. Other symptoms such as rigidity, bradykinesia and gait 
difficulties are found to reduce through stimulation of the subthalamic 
nucleus or the internal segment of the globus pallldius [30]. 
Stem cell treatment
Much research has been conducted on aborted fetuses and the stem 
cells that can be obtained from them. Initially dopaminergic cells were 
experimented with to see if they could be involved in the treatment of 
PD. In one study mesencephalic tissue were obtained from human fetuses 
and grafted into patient’s brains. Patients were found to show significant 
improvement after 6-12 weeks of grafting. Follow up after one year 
showed patients remained stable and furthermore showed improvement 
in complex arm movements (Figure 1) [31]. This study showed promising 
results. However it was based on a sample size of two people.
In another study 6 patients underwent bilateral fetal nigral 
transplantation. This involved grafts from 6 and a 1/2 to 9 week aborted 
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fetuses after conception. Patients were then monitored on how often 
they presented with dyskinesia (involuntary movement), during half an 
hour intervals. Results showed that their daily life activities and motor 
functions improved greatly. In the on phase (moving well) the amount 
of time without dyskinesia increased showing positive results (Figure 2) 
[32]. A limitation with this study was that again it had a small sample 
size making it hard to extrapolate the results to a wider population of 
patients suffering with PD. Furthermore, in Figure 2 you can see that 
in the patients who were monitored for 24 months the amount of time 
in the ‘on’ phase without dyskinesia in fact began to reduce following 
nine months.
Studies carried out later indicated that in fact that the use of fetal 
cells was not as effective as these studies had shown. 34 patients were 
involved in a randomised controlled study. Here some patients received 
fetal nigral transplantation from either one or four donors whilst others 
were placed into a placebo group. The results shows that those in the 
one donor and placebo group in fact showed deterioration whilst those 
in the four-donor group showed improvement. Furthermore, 56% of 
the patients with the transplants when on to develop dyskinesia after 
overnight withdrawal of medicines. These results meant that fetal nigral 
transplantation could not be used as a recommended therapy for PD 
[33]. 
The use of fetal-derived NSCs have been shown to assist in the 
treatment of rodent models suffering from PD. Undifferentiated 
human NSCs were transplanted into 1-methyl-4phenyl-1, 
2,3,6-tetrahydropyridine (MPTP) treated primates. The transplanted 
cells were found to survive, migrate and induce behavioural recovery. 
Tumorogenicity was also found to be minimal [34]. 
Much research has taken place on ESCs involvement in the 
treatment PD. In one study a progenitor population was obtained from 
ESCs. These cells were then increased and encouraged to differentiate 
into dopaminergic neurons and serotonergic neurons. Mitogen and 
specific signaling molecules were used to do this. When the mitogen was 
withdrawn the differentiation and maturation into neurons continued. 
These neurons were found to improve PD. A downside was that 20% 
of the mice went on to develop teratomas [35]. However a study using 
Nur1, a transcription factor that participates in the differentiation 
of dopaminergic cells, showed positive results with no formation of 
tumors. The dopamine neurons showed the same electrophysiological 
and behavioral properties as neurons [27]. The limitation of these 
studies was that the ESCs were derived from mice. Therefore, it makes 
it difficult to extrapolate the findings to humans.
One study that did use human ESCs involved placing them into 
the brains of neonatal mice. Initially the human ESCs developed into 
neural tube-like structure in the presence of FGF-2. The precursors 
were then isolated using enzymatic digestion and purified depending 
on differential adhesion. These precursors were then implanted into 
the mouse brain. They were found to incorporate into various brain 
regions and become both neurons and glial cells. No teratomas were 
found to develop [36]. Despite being human ESCs they were still 
implanted into mice brains making it not possible to extrapolate to 
humans. Furthermore, the use of ESCs raises a lot of safety and ethical 
implications.
In one randomised controlled trial a sample of 40 participants, 
aged 34-75 years suffering from PD, were either given a transplantation 
of human embryonic dopamine neurons or gives a placebo surgery. 
Improvements were seen in the younger patients (60 years and below) 
but no significant improvements were shown in the older patients. In 
addition to this, follow up after the first year showed  recurrence  of 
dyskinesia in 15% of the patients [37]. 
In order to avoid the ethical issues associated with the use of ESCs, 
ASCs have been an attractive therapy to work with as an alternative 
and have been showing some promising results.  In one study MSCs 
Figure 1: Evidence for the use of mesencephalic tissue in treatment of 
Parkinson’s disease. Patient shows reduction in the time taken to perform 
complex arm movement following transplantation of mesencephalic tissue [31].
Figure 2: Reported dyskinesia following bilateral fetal nigral transplantation. 
The top picture shows the mean percentage of time in the ‘on’ phase without 
dyskinesia in 6 patients over 12 months. The bottom picture shows the results 
for 4 patients over 24 months [32].  
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were isolated from the bone marrow of adult rats and cultured. When 
these cells were then placed in an induction medium containing IBMX 
for 2 days they were found to differentiate into neuron-like cells, 
dopaminergic neuron-like cells as well as adipocytes and chondrocytes. 
The neuron like cells were found to express surface markers: Nestin, 
MAP-2a, TH characteristic of neurons at different developmental stages 
(Figure 3). This showed great potential for the use of mesenchymal stem 
cells in the treatment of disorders such as PD [18]. 
A further study, involved isolating NSCs from patients brain. These 
were then cultured and turned into dopamine-producing neurons. 
Following this they were put back inside the patient’s brain. The results 
showed reduction in rigidity and trembling. Brain scans revealed that 
there was a 58% increase in dopamine production. However, this was 
found to drop later but symptoms did not return [38]. 
IPSCs have also shown promising results for the treatment of PD. 
In one study IPSCs were derived from patients suffering from PD 
and differentiated into dopaminergic neurons. These cells were then 
implanted into the striatum of a Parkinsonian rat and were found to 
reduce motor asymmetry [39]. 
Huntington’s Disease
Huntington’s disease (HD) is an autosomal dominant 
neurodegenerative disorder. Patients present with uncontrolled jerky 
movements, in addition to depression and dementia [40]. The disease 
is due to a mutation in the gene coding for the Huntington protein 
resulting from CAG repeats [41]. This genetic mutation occurs mostly 
in the neostriatum causing destruction of GABA-ergic neurons within 
the putamen and caudate nucleus along with gross atrophy. The deep 
layers of the cerebral cortex are also affected. These cellular changes 
explain the chorea (uncontrollable muscle movement) associated with 
HD [42-44]. 
This genetic mutation results in the degeneration of GABA-ergic 
neurons within the caudate-putamen (striatum) and thus explains the 
chorea (uncontrollable muscle movement) associated with HD [42,43]. 
Current treatment 
Like with PD there is no definitive treatment for HD. Despite 
knowing which protein and gene is affected the underlying mechanism 
is still not known [45]. Rather there are drugs such as anti-depressants 
and those that suppress movement that help to alleviate the symptoms. 
Stem cell treatment 
Research utilizing transplantation of fetal human brain tissue has 
shown to be successful in reducing cognitive and motor impairments 
within patient suffering from HD. In one study patients manifesting 
HD had implants of human fetal striatal tissue put into their brain. 
When patients were followed up improvements in functional, cognitive 
and motor abilities were found [45]. The results from this study were 
consistent with those of a study carried out that same year which also 
involved grafting of human fetal striated tissue into patients suffering 
from HD [42]. 
Because the tissue being grafted did not go on to develop any 
mutation this method seemed to offer good hope in replacing the 
damaged neurons affected by the disease process of HD. However, the 
limitation of using fetal derived tissue to treat HD is the difficulty in 
obtaining large amounts of it without overstepping ethical boundaries 
[9]. 
Another potential source for treating HD has been through the 
use of NSCs. These can either be those isolated from embryos or from 
adults. One study took neural precursor cells that were transplanted into 
rat models suffering from HD. The neural precursor cells were found 
to differentiate and when observed expressed antigens characteristic of 
neurons. This meant that a striatal phenotype had been achieved. The 
neurons were found to have diffused throughout the brain of the rats 
[46]. 
Further studies have been carried out which supports this research. 
In one study stem cells were obtained from the cortex of human fetuses, 
which were then transplanted into rats. These rats had been injected 
with quinolinic acid into their striatum in order to resemble patients 
suffering from HD. The quinolinic acid being a toxin causes death of the 
striatum. The results shows that the rats receiving the transplantation 
had a 22% increase in their striatal volume when compared to the rats 
who had been given a sham injection [47]. 
The positive effects of NSCs are thought to be due to the release of 
brain derived neurotropic factor (BDNF) released by the NSCs that have 
been transplanted. Evidence for the positive effects of BDNF also came 
from a study involving three groups of rats. One group was treated with 
BDNF, whilst another with beta-galactosidase and a third group who 
were the control, thus, were not treated with anything. Following this, 
the three groups were then given lesions of quinolinic acid to mimic the 
effects of HD. The results showed that the rats treated with BDNF had 
more cells surviving over the other two groups [43]. 
The results of this study were supported by a similar experiment 
carried out the following year where cell lines expressing BDNF were 
transplanted into the striatum of adult rats. Following this they were 
injected with quinolinic acid and the cell loss was found to be less 
than the control group. Other neurotrophins: neurotrophin-3 and 
neurotrophin-4/5 showed a decrease in cell loss also but to a lesser 
extent when compared to BDNF [48]. 
Transplantation of these cells requires very invasive surgery. A 
better approach would be to devise a method in which these NSCs could 
be injected intravenously. This approach was tried on animal models 
that again were treated with quinolinic acid. Results showed a reduction 
in the death of striatal neurons when compared to the control [49]. 
Compared to transplantation, this approach of intravenous injection is 
much more advantageous due to its less invasive properties.
Figure 3: Differentiation of Mesenchymal Stem Cells. Mesenchymal cells after 
being induced for 15 days. Show positive for TH; a marker for dopaminergic 
neurons [18]. 
Citation: Blundell R, Shah M (2015) Neurodegenerative Diseases and Stem Cell Transplantation. J Stem Cell Res Ther 5: 277. doi:10.4172/2157-
7633.1000277
Page 6 of 9
Volume 5 • Issue 4 • 1000277
J Stem Cell Res Ther
ISSN: 2157-7633 JSCRT, an open access journal 
In addition to the positive potential shown by NSCs when it comes 
to treating PD, are IPSCs. In one study IPSCs were derived from the 
fibroblasts of HD patients. Through homologous recombination the 
CAG repeat was replaced with a normal repeat. When the IPSCs were 
then differentiated into neurons, the correction was found to remain. 
Furthermore, it was found that the phenotypes associated with HD and 
the pathogenic signaling pathways were reversed [50]. 
Alzheimer’s Disease
Alzheimer's disease (AD) is estimated to be the most common type 
of dementia affecting mainly people over the age of 65 [51]. Causes of 
AD are linked to mutations, which leads to increased production of 
the β-amyloid peptide. When this peptide forms aggregates it becomes 
toxic to the brain forming neuritic plaques. Characteristic to Alzheimer 
patients are also neurofibrillary tangles [52]. 
Alzheimer's disease (AD) is estimated to be the most common 
type of dementia affecting mainly people over the age of 65 [51]. 
Causes of AD are linked to mutations, which lead to increased 
production of the B-amyloid peptide. When this peptide aggregates, 
it forms neuritic plaques that then become toxic to the brain [48]. 
Characteristic of Alzheimer patients are also neurofibrillary tangles, 
synpatic deterioration and death of neurons [53]. It is thought that 
the amyloid plaques affect the activity of the synapse initiating a 
number of downstream effects leading to dysfunctional interneuronal 
transmission and inevitably cell death [54]. 
Evidence shows that Alzheimer patients also suffer from loss of 
acetylcholine neurons and synapses and therefore reduction in the 
amount of neurotransmitters released. These neurons are thought to 
relate to memory, thus loss of them accounts for the manifestation of 
dementia. Loss of neurons takes place throughout the cortical area, 
basal forebrain, hippocampus and amygdala [55,56]. 
 Current treatment 
To assist with the management of AD and aiming to increase 
the level of neurotransmitter in the brain acetylcholinesterase 
inhibitors are given to patients. This slows down the breakdown of 
the neurotransmitter acetylcholine [57]. This treatment is effective in 
managing the symptoms; however it is not a cure and therefore, shows 
how necessary the finding of a definitive treatment is.
 Stem cell treatment 
Like seen in other neurodegenerative disorders discussed 
previously: Parkinson’s and Huntington’s disease, there is evidence also 
showing that stem cells have a large part to participate in the treatment 
of AD.
One study showed promise for the use of NSCs derived from ESCs 
but showed less hope for the use of ESCs alone in their treatment for 
Alzheimer’s. The NSCs derived from ESCs were transplanted into the 
frontal association cortex of a mouse model of AD.
Results showed that the stem cells survived and went on to 
differentiate into cholinergic neurons. Memory was also found to 
improve. The control group who received ESCs alone went on to 
develop teratomas (Figure 4) [58].
Similar to HD there is evidence showing that the BDNF can help 
to improve the symptoms of AD. In one study NSCs were transplanted 
into mouse brains that expressed aggregates of brain plaques and 
tangles. Results showed that, following transplantation, memory and 
learning improved. The NSCs were found not to reduce the levels of 
β-amyloid levels but rather increase the levels of BDNF, which lead to 
an increase in the number of synapses [52]. 
Like with PD and HD, IPSC’s have also shown promise in the 
treatment of AD. Neuronal stem cells were successfully created from the 
fibroblasts present in adults suffering from PD and healthy individuals. 
This shows great hope for the use of IPSCs in the treatment of AD [59]. 
Multiple Sclerosis
Multiple Sclerosis (MS) is often recognised pathologically by the 
presence of plaques of inflammatory demyelination. These plaques can 
be classified into acute, chronic active and chronic silent stages based 
on their progression of inflammatory destruction. The end stage of 
these plaques is characteristic of loss of oligodendrocytes and myelin 
surrounding the axon at the cellular level and scarred hardened areas 
that can be visualised grossly [60]. This process results in patients 
presenting with symptoms of numbness and tingling, visual problems 
and some can experience pain [61]. 
 Current treatment
As there is currently no treatment for MS there are numerous 
therapies that have been approved by the FDA which are used to reduce 
the episodes of symptoms associated with MS (Table 1). Many work in 
such a way as to moderate the immune system with MS being caused 
by an inflammatory-mediated process [61]. There is evidence showing 
immune moderations are an effective treatment but a full functional 
Figure 4: Stain of healthy neurons and teratomas. a) HE stain showing healthy neurons derived from NSC transplantation. b) Teratomas derived from ESC 
transplantation [58]. 
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recover in many patients is not witnessed [62]. Furthermore, it seems 
that these drugs are only able to manage the early relapses that occur 
MS [63]. Therefore, discovery of another treatment is needed. 
Stem cell treatment
As MS is characterized by loss of myelin and oligodendrocytes 
finding a way to replace this would serve as a very good treatment. One 
study utilised shiverer demyelination mutant mice. These were mice 
that had lesions induced to mimic the characteristics of MS. Fragments 
of newly born mice were implanted into the brains of the shiverer 
mice. Results showed there was large amount of myelination over long 
distances [64], thus showing hope for the treatment of MS. In another 
study CG4 oligodendrocyte progenitor cells were labelled with blue and 
grafted into the brains of rat pups that were deficient in myelin. After 
two weeks, results showed extensive migration, synthesis of myelin 
components and myelin formation along the axons of various parts of 
the brain when compared to the control [65]. This showed great hope 
for a potential treatment in MS.
There is much research looking into the role of ESCs in the treatment 
of MS. In this study 24 patients made up of 14 women and 10 men 
were administered ESCs from 4-8 week year old embryos. They were 
either administered intravenously, subcutaneously or intracavitary. 
The results shown were promising. 70% off the patients showed signs 
of improvements soon after the transplantation. These improvements 
consisted of decreased weakness and improvement on appetite and 
mood. Follow up after a month showed reduction in nystagmus, 
convergence disturbance and spasticity. Improvements in dysarthria, 
dysphagia, and ataxia were much slower. In general improvements were 
found in the extremities. There was decrease in tiredness and general 
weakness, normalization of muscle tone as well as an improvement in 
the quality of life. 87% of patients were found to report no worsening or 
further progression of the disease. An MRI taken 1-2 years after showed 
a reduction in the focal lesions [38]. 
More promising than what has been discussed is the role of bone 
marrow transplants where the patients are their own donors in the 
treatment of MS. Research indicates that this is the most effective 
form of treatment. It is thought to work by re-setting the patient’s own 
immune system and having them ‘regenerate an antigen-naïve immune 
system’ from their own HSCs [10,63]. Patients own HSCs are obtained 
and stored whilst they undergo intense chemotherapy. Following this, 
their immune system is regenerated from the HSCs previously stored. 
Results have shown that patients who experienced severe episodes 
before treatment, found them to be reduced or completely eliminated 
following the treatment [66]. 
NSCs have also found to be useful in the treatment of MS. In 
one study adult NSCs were given to mouse models of MS, either 
intravenously or intracerebroventricularly. Results showed that these 
NSCs when administered via either method appeared in areas where 
demyelination had taken place, and went on to differentiate into mature 
cells. Axons were also found to be remyelinated (Figure 5) [67]. 
NSCs in undifferentiated form have also been found to have 
an anti-inflammatory effect, which provides useful in treating MS 
with it being a chronic inflammatory mediated process. In one study 
neural precursor cells were found to cause apoptosis of T cells causing 
inflammation of the brain (encephalitis) and further protected against 
loss off neural tissue [67]. 
It seems that there are many avenues being explored for the 
treatment of MS. Autologous bone marrow transplants seem to show 
much hope. NSCs with their role of protecting against inflammation 
and ability to replace lost myelin also show great potential.
Conclusion
Our insight into stem cells has come a long since they were first 
referred to in the early 1900’s and from the evidence being generated it 
seems there is great potential for future groundbreaking research. 
From the current research that has been undertaking it seems there 
is big role for stem cells to play in the treatment of neurodegenerative 
disorders. A variety of sources of stem cells: embryonic, bone marrow 
derived, neural, induced pluripotent and umbilical are showing great 
hope. However, at the same time each has their limitations. The method 
chosen therefore when treating neurodegenerative disorders will 
need to have low side effects associated with it, be cost effective, easily 
Drug Brand (Manufacturer) Recommended Dose Dosing Frequency Route
Interferon beta- I a Avonex (Biogen Idec) 30 mcg Once weekly IM
Interferon beta- I a Rebif (Pfizer) 22 or 44 mcg Three times weekly SQ
Interferon beta- I b Betaseron (Bayer) 0.25 mg Every other day SQ
Interferon beta- I b Extavia (Novartis) 0.25 mg Every other day SQ
Glatiramer acetate Copaxone (Teva) 20 mg Once daily SQ
Mitoxantrone Novantrone (EMD Serono) 5 to 12 mg/m2 Short infusion (about 5 to 15 minutes) every 3 months IV
Natalizumab Tysabri (Biogen Idec) 300 mg 1- hour infusion every 4 weeks IV
Fingolimod Gilenya (Novartis) 0.5 mg Once daily PO
IM: Intramuscular; IV: Intravenous; PO: Per as (by mouth); SQ: Subcutaneous
Table 1: FDA-approved drug therapies for Multiple sclerosis [61]. 
Figure 5: Light microscopy of transplanted neural stem cells. Light microscopy 
showing transplanted neural stem cells contributing to myelination of axons. 
‘n’ indicates the nucleus of the neural stem cells, with blue deposits going to 
surround the axon (arrows) surrounded by myelin (dashed arrows). The short 
arrowheads represent thin layer of myelin [68]. 
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replicated on a large scale and avoid ethical issues when it comes to 
obtaining cells.
It was the norm at the time of Ramon y Cajal to believe neurogenesis 
did not occur. It is exciting to wonder what facts we believe now to 
be true will be disproved in the future in addition to what other 
groundbreaking new research will be made, opening the door to future 
potentialities in treatment of illness and disease.
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